| Primary |
| Product Used For Unknown Indication |
50.0% |
| Pulmonary Arterial Hypertension |
50.0% |
|
| Death |
50.0% |
| Drug Dose Omission |
50.0% |
|
| Secondary |
| Ill-defined Disorder |
25.6% |
| Hypotension |
17.4% |
| Drug Use For Unknown Indication |
9.3% |
| General Anaesthesia |
7.0% |
| Chronic Obstructive Pulmonary Disease |
5.8% |
| Maintenance Of Anaesthesia |
4.7% |
| Premedication |
4.7% |
| Induction Of Anaesthesia |
3.5% |
| Product Used For Unknown Indication |
3.5% |
| Stridor |
3.5% |
| Neuromuscular Blockade Reversal |
2.3% |
| Perioperative Analgesia |
2.3% |
| Procedural Pain |
2.3% |
| Anaesthesia |
1.2% |
| Antibiotic Prophylaxis |
1.2% |
| Cardiogenic Shock |
1.2% |
| Chest Pain |
1.2% |
| Dyspnoea |
1.2% |
| Intubation |
1.2% |
| Multiple Myeloma |
1.2% |
|
| Mesothelioma |
15.8% |
| Tachypnoea |
15.8% |
| Vomiting |
10.5% |
| Compression Fracture |
5.3% |
| Condition Aggravated |
5.3% |
| Drug Ineffective |
5.3% |
| Dyspnoea |
5.3% |
| Hypovolaemia |
5.3% |
| Pneumonia |
5.3% |
| Post Procedural Complication |
5.3% |
| Pulmonary Haemorrhage |
5.3% |
| Pulmonary Oedema |
5.3% |
| Respiratory Disorder Neonatal |
5.3% |
| Sedation |
5.3% |
|
| Concomitant |
| Pulmonary Hypertension |
22.8% |
| Pulmonary Arterial Hypertension |
22.5% |
| Immunodeficiency Common Variable |
7.5% |
| Chronic Obstructive Pulmonary Disease |
7.3% |
| Multiple Myeloma |
6.9% |
| Cor Pulmonale Chronic |
4.4% |
| Pain |
3.7% |
| Ill-defined Disorder |
3.2% |
| General Anaesthesia |
3.0% |
| Non-small Cell Lung Cancer |
2.9% |
| Postpartum Haemorrhage |
2.4% |
| Drug Use For Unknown Indication |
2.0% |
| Induction Of Anaesthesia |
2.0% |
| Multiple Sclerosis |
1.7% |
| Emphysema |
1.6% |
| Alpha-1 Anti-trypsin Deficiency |
1.2% |
| Asthma |
1.2% |
| Maintenance Of Anaesthesia |
1.2% |
| Anaesthesia |
1.1% |
| Back Pain |
1.0% |
|
| Pneumonia |
10.3% |
| Respiratory Failure |
9.4% |
| Dyspnoea |
9.1% |
| Death |
8.0% |
| Vomiting |
6.6% |
| Right Ventricular Failure |
6.0% |
| Weight Decreased |
6.0% |
| Hypotension |
5.4% |
| Drug Ineffective |
5.1% |
| Pulmonary Hypertension |
4.0% |
| Weight Increased |
3.7% |
| Respiratory Distress |
3.1% |
| Unresponsive To Stimuli |
3.1% |
| Wheezing |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Liver Disorder |
2.8% |
| Sudden Death |
2.8% |
| Thrombosis |
2.8% |
| Urinary Tract Infection |
2.8% |
| Off Label Use |
2.6% |
|
